Image source social media
Image source social media
New Delhi, Jan 04: Along with Corona, there is an alarming increase in the cases of Omicron in the country. In other parts of the country including Delhi, Maharashtra, the graph of new patients is increasing continuously. Meanwhile, drugmaker Dr Reddy's Laboratories Limited will soon launch its generic version of the anti-viral Covid-19 drug Molflu (molnupiravir). Giving this information on Tuesday, a spokesperson of the pharmaceutical company said that its price would be Rs 35 per capsule. American pharmaceutical company Merck's anti-covid drug 'Molflu' will cost Rs 1400 for a 5-day course in India.
Hyderabad-based drugmaker Dr Reddy's Laboratories said in its statement that each strip of this generic drug, sold under the name 'Molflu', will contain 10 capsules. The patient will run a 5-day course with 40 capsules, which will cost a total of Rs 1,400. In comparison, the cost of treatment with Merck's pill in the US is $ 700, or 52,219.
Covid antiviral drug #Molnupiravir was launched in #India at Rs 1,399 for a five-day course for mild to moderate infection. pic.twitter.com/3pKtTe1XrR— IANS Tweets (@ians_india) January 4, 2022
India approved the drug last week
Giving information about the drug, a company spokesperson said that Molflu is expected to be available in pharmacies across India from early next week, with a special focus on states with a high caseload of COVID-19. This drug will be more useful for those patients who are high-risk patients of the corona. The Drug Controller General of India (DCGI) last week approved Molnupiravir for emergency use along with two vaccines, as the country's fast-spreading Omicron variant continues to increase the number of coronavirus cases.
13 companies in India to make Molnupiravir With a view to make India a manufacturing hub, Merck has entered into licensing agreements with eight domestic drug manufacturers, including Dr Reddy's, to manufacture and supply generic versions of Molnupiravir to over 100 low and middle-income countries. With a view to transforming India into a manufacturing hub, Merck has entered into licensing agreements with eight domestic drug manufacturers, including Dr Reddy's, to manufacture and supply generic versions of Molnupiravir in over 100 low and middle-income countries. Health Minister Mansukh Mandaviya said last week that a total of 13 companies in India would make Molnupiravir.
India reported 37,379 new COVID-19 cases on Tuesday, its highest since early September.